D-Mannose

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: immunity detox digestion

Research Overview

Across the studies, D-mannose research is most developed in immunology/oncology and inflammation-related disease models, with additional attention in urology. Mechanistic studies in cancer and T-cell biology describe D-mannose as a metabolic modulator that can reshape immune cell state: supplementation is reported to restore mannose metabolism in dysfunctional CD8 T cells, increase OGT-mediated O-GlcNAcylation of β-catenin, preserve Tcf7 expression and “stem-like” programs, and thereby enhance anti-tumor activity in adoptive cell therapy models. In tumor cells, D-mannose is also reported to promote PD-L1 degradation via AMPK-dependent phosphorylation and altered glycosylation, improving T-cell–mediated killing and synergizing with PD-1 blockade and radiotherapy in mouse TNBC models. Separately, a clinical-need–driven literature evaluates D-mannose as a non-antibiotic approach for recurrent UTI prevention/treatment, but the cited review emphasizes that evidence is promising yet not definitive and that higher-quality trials are required.

The strongest evidence in these studies is preclinical and mechanistic: multiple mouse and in vitro systems support that D-mannose can influence immune checkpoints (PD-L1 stability), T-cell differentiation/exhaustion trajectories, and inflammatory cell-death susceptibility (ferroptosis) in chondrocytes, with reported disease-modifying effects in models of TNBC and osteoarthritis. A separate preclinical line suggests anti-inflammatory/anti-nociceptive properties relevant to chronic pain, identified during development of non-viral IL-10 gene therapy formulations. Collectively, these studies support a coherent theme that D-mannose can alter glycosylation-linked signaling and cellular metabolic programming, with downstream effects on immune activation and inflammatory pathology; however, the strength of inference for human benefit remains limited by the predominance of animal and cell-culture data in the mechanistic areas.

Key gaps include translation to humans: dose–exposure relationships, safety and tolerability at therapeutically relevant levels, and efficacy in well-powered randomized controlled trials—particularly for oncology adjunct use (with checkpoint blockade, radiotherapy, or adoptive T-cell therapy), osteoarthritis disease modification, and chronic pain. For UTIs, the need is for high-level clinical evidence in defined populations and standardized endpoints, as highlighted by the review. Additional research is also needed to clarify context dependence (e.g., when mannose-driven glycosylation changes benefit host immunity versus potentially affecting other pathways), identify biomarkers of response, and delineate interactions with the microbiome and with mannose-containing polysaccharides (which are mechanistically distinct from free D-mannose but relevant to glycan biology and host–microbe metabolism).

1. What conditions has D-Mannose been studied for?

  • Urinary tract infections (UTIs) (prevention and treatment), particularly recurrent UTIs, as a non-antibiotic anti-adhesive strategy against uropathogenic E. coli (FimH-mediated adhesion).

  • Cancer immunotherapy/oncology (preclinical):

    • Triple-negative breast cancer (TNBC): studied as an adjunct to immunotherapy (PD-1 blockade) and radiotherapy, via effects on PD-L1 stability (mouse models).

    • Adoptive T-cell therapy: studied to improve CD8 T-cell “stemness” and reduce exhaustion, enhancing anti-tumor activity (in vitro and in vivo models).

  • Osteoarthritis (OA) (preclinical): studied for chondroprotection by reducing chondrocyte ferroptosis sensitivity in an ACLT-induced OA mouse model and IL-1β–stimulated chondrocytes.

  • Pain/inflammation (preclinical, review-level): described as having anti-nociceptive, anti-inflammatory properties discovered in the context of non-viral IL-10 gene therapy formulations (mechanistic/preclinical discussion).

  • Inflammatory bowel disease/ulcerative colitis (UC): the provided UC abstract uses mannose as a targeting ligand in a drug-delivery system (mannose-modified nanoparticles) rather than oral D-mannose supplementation itself.

2. Does it work in treating those conditions? Summarize the evidence.

  • UTIs: Evidence is suggestive but not definitive.

    • A UTI review notes D-mannose as a potential nonantibiotic option, but emphasizes that high-level evidence is required before firm recommendations.

    • A Cochrane-style review abstract states that anti-adhesive effects are well-established mechanistically, and that early pilot studies and small clinical trials (doses roughly 200 mg to 2–3 g) reported possible efficacy in reducing symptoms or recurrence; however, it highlights the limited size/quality of the clinical evidence base.

  • TNBC / cancer therapy (preclinical): Promising in mice, not proven in humans.

    • D-mannose activated AMPK leading to PD-L1 phosphorylation (S195), abnormal glycosylation, and proteasomal degradation of PD-L1, which increased T-cell activation and tumor cell killing in models.

    • Combination of D-mannose with PD-1 blockade “dramatically” inhibited TNBC growth and extended survival in tumor-bearing mice; it also sensitized tumors to ionizing radiation in mice.

    • Key limitation: these are animal and mechanistic studies; clinical efficacy and safety for cancer treatment are not established from these studies.

  • Adoptive T-cell therapy (preclinical): Mechanistic and translationally oriented, but still not clinical proof.

    • Single-cell metabolic analyses associated T-cell dysfunction with diminished mannose metabolism; D-mannose supplementation during expansion/transfer enhanced anti-tumor activity and restricted exhaustion differentiation in vitro and in vivo.

    • Mechanism described: increased OGT-mediated O-GlcNAcylation of β-catenin, preserving Tcf7 expression and “epigenetic stemness.”

  • Osteoarthritis (preclinical): Beneficial in mouse and cell models.

    • D-mannose reduced chondrocyte sensitivity to ferroptosis and alleviated OA progression in an ACLT mouse model.

    • Effect depended on HIF-2α (EPAS1): overexpression of HIF-2α abolished D-mannose’s chondroprotective/anti-ferroptotic effects.

    • Limitation: no human OA trials are provided in these studies.

  • Pain/inflammation (preclinical/review): Suggestive, not clinical evidence.

    • A review describes “powerful anti-nociceptive anti-inflammatory properties” of D-mannose discovered as an adjuvant in IL-10 gene therapy research, but does not provide clinical trial outcomes in the study.

3. What health benefits does it have?

  • Anti-adhesion benefit in UTIs: D-mannose can block uropathogenic E. coli adhesion/invasion of uroepithelial cells (consistent with FimH-mediated binding concepts), potentially reducing symptoms or recurrence and supporting a non-antibiotic approach.

  • Immune modulation in cancer models:

    • May enhance CD8 T-cell function and reduce exhaustion differentiation via metabolic programming and O-GlcNAcylation pathways.

    • May reduce tumor immune evasion by promoting PD-L1 degradation (TNBC mouse models), potentially improving response to PD-1 blockade and radiotherapy.

  • Potential joint/cartilage protection (preclinical): In OA models, D-mannose reduced ferroptosis susceptibility in chondrocytes and slowed OA progression, with HIF-2α as a key mediator.

  • Anti-inflammatory/anti-nociceptive signals (preclinical/review): Discussed as having anti-inflammatory properties relevant to cytokine-driven pain pathways, though clinical relevance is not established in the studies reviewed here.

4. Does it have any downsides or side effects?

The studies reviewed here contain limited direct safety/side-effect reporting for oral D-mannose in humans.

  • Evidence limitations: The UTI-focused studies emphasize that existing studies are small/pilot in nature and that stronger evidence is needed; this also implies that uncommon adverse effects may be under-characterized.

  • Population considerations: The UTI background notes higher-risk groups (e.g., immunosuppressed, chronic kidney disease) but does not provide D-mannose-specific harm data in these groups.

  • Preclinical dosing note: The TNBC abstract states effective levels were “easily achieved by oral administration in mice,” but does not provide human tolerability or adverse event rates.

Overall, based on these studies alone, no specific side effects can be confidently listed; the main “downside” supported here is the current lack of high-quality human safety and efficacy data for most proposed uses beyond UTIs.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

No human pharmacogenomic findings are directly reported in the studies reviewed here. However, two mechanistic points suggest plausible gene-dependent effects (not proven clinically):

  • EPAS1 (HIF-2α) pathway (osteoarthritis models): D-mannose’s chondroprotective, anti-ferroptotic effect depended on HIF-2α activity; experimental overexpression of Epas1 abolished benefit. This suggests that genetic or regulatory variation increasing HIF-2α signaling could theoretically reduce responsiveness, but this has not been tested in humans.

  • O-GlcNAc transferase (OGT) / β-catenin / Tcf7 axis (T-cell studies): D-mannose increased OGT-mediated O-GlcNAcylation of β-catenin and preserved Tcf7 expression in T cells. Variants affecting these pathways could plausibly alter response, but no genotype-stratified outcomes are provided.

Conclusion: pharmacogenomic guidance cannot be made from these studies; any gene-response relationships remain hypothesis-generating.

References

  1. Xanthan gum in aqueous solutions: Fundamentals and applications.
    Emmanuel M Nsengiyumva, Paschalis Alexandridis (2022) - International journal of biological macromolecules
  2. Mannose metabolism reshapes T cell differentiation to enhance anti-tumor immunity.
    Yajing Qiu, Yapeng Su, Ermei Xie, Hongcheng Cheng, Jing Du, Yue Xu, Xiaoli Pan, Zhe Wang, Daniel G Chen, Hong Zhu, Philip D Greenberg, Guideng Li (2025) - Cancer cell
  3. Glycosidic linkages of fungus polysaccharides influence the anti-inflammatory activity in mice.
    Qin Yuan, Wen Liu, Wei Hao, Yi Chen, Yaqin Xiao, Hongyi Li, Mingju Shui, Ding-Tao Wu, Shengpeng Wang (2025) - Journal of advanced research
  4. D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1.
    Ruonan Zhang, Yajing Yang, Wenjing Dong, Mingen Lin, Jing He, Xinchao Zhang, Tongguan Tian, Yunlong Yang, Kun Chen, Qun-Ying Lei, Song Zhang, Yanping Xu, Lei Lv (2022) - Proceedings of the National Academy of Sciences of the United States of America
  5. Nonantibiotic prevention and management of recurrent urinary tract infection.
    Néha Sihra, Anna Goodman, Rhana Zakri, Arun Sahai, Sachin Malde (2018) - Nature reviews. Urology
  6. Cytokines in Pain: Harnessing Endogenous Anti-Inflammatory Signaling for Improved Pain Management.
    Arden G Vanderwall, Erin D Milligan (2019) - Frontiers in immunology
  7. "Dual sensitive supramolecular curcumin nanoparticles" in "advanced yeast particles" mediate macrophage reprogramming, ROS scavenging and inflammation resolution for ulcerative colitis treatment.
    Xiaoqin Han, Ruifeng Luo, Shanshan Qi, Yanli Wang, Linxin Dai, Wenbiao Nie, Meisi Lin, Haoqi He, Naijing Ye, Chaomei Fu, Yu You, Shu Fu, Fei Gao (2023) - Journal of nanobiotechnology
  8. FimH and Anti-Adhesive Therapeutics: A Disarming Strategy Against Uropathogens.
    Meysam Sarshar, Payam Behzadi, Cecilia Ambrosi, Carlo Zagaglia, Anna Teresa Palamara, Daniela Scribano (2020) - Antibiotics (Basel, Switzerland)
  9. D-mannose for preventing and treating urinary tract infections.
    Tess E Cooper, Claris Teng, Martin Howell, Armando Teixeira-Pinto, Allison Jaure, Germaine Wong (2022) - The Cochrane database of systematic reviews
  10. Injectable Ozone-Rich Nanocomposite Hydrogel Loaded with D-Mannose for Anti-Inflammatory and Cartilage Protection in Osteoarthritis Treatment.
    Hangtian Wu, Jun Wang, Yanpeng Lin, Wanling He, Jiahui Hou, Mingye Deng, Yupeng Chen, Qinwen Liu, Aiping Lu, Zhuang Cui, Daogang Guan, Bin Yu (2024) - Small (Weinheim an der Bergstrasse, Germany)
  11. Mannose: a potential saccharide candidate in disease management.
    M Dhanalakshmi, D Sruthi, K R Jinuraj, Kajari Das, Sushma Dave, N Muthulakshmi Andal, Jayashankar Das (2023) - Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents
  12. Role of D-mannose in urinary tract infections - a narrative review.
    Reeta Ala-Jaakkola, Arja Laitila, Arthur C Ouwehand, Liisa Lehtoranta (2022) - Nutrition journal
  13. Role of D-Mannose in the Prevention of Recurrent Urinary Tract Infections: Evidence from a Systematic Review of the Literature.
    Rena Kyriakides, Patrick Jones, Bhaskar K Somani (2021) - European urology focus
  14. PMI-controlled mannose metabolism and glycosylation determines tissue tolerance and virus fitness.
    Ronghui Liang, Zi-Wei Ye, Zhenzhi Qin, Yubin Xie, Xiaomeng Yang, Haoran Sun, Qiaohui Du, Peng Luo, Kaiming Tang, Bodan Hu, Jianli Cao, Xavier Hoi-Leong Wong, Guang-Sheng Ling, Hin Chu, Jiangang Shen, Feifei Yin, Dong-Yan Jin, Jasper Fuk-Woo Chan, Kwok-Yung Yuen, Shuofeng Yuan (2024) - Nature communications
  15. The Molecular Mechanisms and Therapeutic Potential of Cranberry, D-Mannose, and Flavonoids against Infectious Diseases: The Example of Urinary Tract Infections.
    Petros Ioannou, Stella Baliou (2024) - Antibiotics (Basel, Switzerland)
  16. D-Mannose Regulates Hepatocyte Lipid Metabolism
    Mengyao Hu, Yu Chen, Fan Deng, Bo Chang, Jialiang Luo, Lijun Dong, Xiao Lu, Yi Zhang, Zhengliang Chen, Jia Zhou (2022) - Frontiers in immunology
  17. Characterization of a novel recombinant D-mannose isomerase from Bifidobacterium bifidum and its catalytic mechanism.
    Shuang Xiao, Xiaoqiao Luo, Peng Zhang, Guowen Zhang, Xing Hu (2024) - Enzyme and microbial technology
  18. D-mannose alleviates intervertebral disc degeneration through glutamine metabolism.
    Zheng-Lin Dong, Xin Jiao, Zeng-Guang Wang, Kai Yuan, Yi-Qi Yang, Yao Wang, Yun-Tao Li, Tian-Chang Wang, Tian-You Kan, Jian Wang, Hai-Rong Tao (2024) - Military Medical Research


Related

This article summarizes published research for educational purposes. It is not medical advice. Talk to your doctor before starting, stopping, or changing any supplement or medication.

Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!